Zdravlje/Frontier Biopharma has received another Marketing Authorisation in the CEE issued by the Bulgarian Drug Agency for PazoFront® 200mg and 400mg, film-coated tablets (INN: pazopanib). PazoFront’s active substance (pazopanib) is a protein kinase inhibitor that works by preventing the activity of proteins involved in the growth and spread of cancer cells.